Background/Aims Although hepatocellular carcinoma (HCC) is notorious for its high recurrence rate, some patients do not experience recurrence for more than 5 years after resection or radiofrequency ablation for early-stage HCC. For those with five recurrence-free period, the risk of HCC recurrence within the next 5 years remains unknown.
Methods A total of 1,451 consecutive patients (median, 55 years old; males, 79.0%; hepatitis B virus-related, 79.3%) with good liver function (Child-Pugh class A) diagnosed with early-stage HCC by Barcelona Clinic Liver Cancer Staging and received radiofrequency ablation or resection as an initial treatment between 2005 and 2010 were analyzed.
Result s: During a median follow-up period of 8.1 years, 961 patients (66.2%) experienced HCC recurrence. The cumulative recurrence rates increased to 39.7%, 60.3%, and 71.0% at 2, 5, and 10 years, respectively, and did not reach a plateau. Five years after HCC diagnosis, 487 patients were alive without experiencing a recurrence. Among them, during a median of 3.9 additional years of follow-up (range, 0.1–9.0 years), 127 patients (26.1%) experienced recurrence. The next 5-year cumulative recurrence rate (5–10 years from initial diagnosis) was 27.0%. Male sex, higher fibrosis-4 scores, and alpha-fetoprotein levels at 5 years were associated with later HCC recurrence among patients who did not experience recurrence for more than 5 years.
Conclusions The HCC recurrence rate following 5 recurrence-free years after HCC treatment was high, indicating that HCC patients warrant continued HCC surveillance, even after 5 recurrence-free years.
Citations
Citations to this article as recorded by
Entinostat suppresses hepatocellular carcinoma metastasis by upregulating AZGP1 through histone acetylation Weiguo Cai, Xinru Pei, Xiaodie Ye, Yan Zhai, Na Wu, Ziyi Wang, Wei Lu Biochemical Pharmacology.2026; 246: 117718. CrossRef
Cure after surgery for hepato-pancreato-biliary cancers: A systematic review Marianna Maspero, Carlo Sposito, Vincenzo Mazzaferro, Giorgio Ercolani, Alessandro Cucchetti Digestive and Liver Disease.2025; 57(1): 1. CrossRef
What Is the Optimal Locoregional Approach for Recurrent Hepatocellular Carcinoma? Neil B. Newman, Colin M. Court, Alexander A. Parikh Journal of Clinical Oncology.2025; 43(9): 1050. CrossRef
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review Edoardogregorio Galli, Giorgio Patelli, Federica Villa, Nicole Gri, Chiara Mazzarelli, Iacopo Mangoni, Cristiano Sgrazzutti, Silvia Ghezzi, Andrea Sartore-Bianchi, Luca Saverio Belli, Luciano De Carlis, Angelo Vanzulli, Salvatore Siena, Katia Bencardino Cancer Treatment Reviews.2025; 135: 102908. CrossRef
Extrahepatic Recurrence After Surgical Resection of Hepatocellular Carcinoma Without Intrahepatic Recurrence: A Multi-Institutional Observational Study Ga Ram You, Shin Young Park, Su Hyeon Cho, Sung Bum Cho, Yang Seok Koh, Chang Hun Lee, Hoon Gil Jo, Sung Kyu Choi, Jae Hyun Yoon Cancers.2025; 17(9): 1417. CrossRef
Mesenchymal circulating tumor cells as prognostic markers in HCC Post-Transplantation: Sirolimus as a potential therapeutic Modulator Jinyan Chen, Rongsen Wang, Huigang Li, Jiancai Sun, Ruijie Zhao, Jianyong Zhuo, Zuyuan Lin, Chiyu He, Xingzhu Chen, Jun Li, Leyi Chen, Xudong Yang, Xuyong Wei, Shusen Zheng, Xiao Xu, Di Lu European Journal of Surgical Oncology.2025; 51(9): 110147. CrossRef
Predictors of long-term survival outcomes of patients with hepatocellular carcinoma without recurrence at five years after liver resection Cheng-Ying Hsieh, Chee-Chien Yong, Yueh-Wei Liu, Wei-Feng Li, Chih-Chi Wang, Yi-Hao Yen, Chih-Yun Lin Langenbeck's Archives of Surgery.2025;[Epub] CrossRef
Landscape of T-cell exhaustion heterogeneity and HBV integration in virus-related HCC revealed by whole-exome, transcriptome, and single-cell sequencing Soon Kyu Lee, Jinyeong Lim, Joo Yeon Jhun, Jeonghyeon Moon, Hye Seon Kim, Jong Young Choi, Ho Joong Choi, Young Kyoung You, Ji Won Han, Pil Soo Sung, Kwon Yong Tak, Seung Kew Yoon, Woong-Yang Park, Mi-La Cho, Jeong Won Jang JHEP Reports.2025; 7(11): 101518. CrossRef
Targeting STAT3 by erianin to overcome sorafenib resistance in hepatocellular carcinoma: Integrated network pharmacology with molecular docking, dynamics simulations, and in vitro validation Zixian Liu, Ruoning Qian, Yuanchao Feng, Ruogu Qi, Zhengguang Zhang, Fuqiong Zhou Biochemical and Biophysical Research Communications.2025; 778: 152348. CrossRef
Relative survival among cancer survivors enrolled in private cancer insurance in Japan, using the internal insurance-enrolled population as the reference Makoto Hiraoka, Hayaka Uekusa, Akira Okada, Reiko Inoue, Kayo Ikeda-Kurakawa, Yusuke Otsuka, Daisuke Namiki, Ryuichi Yamamoto, Toshimasa Yamauchi, Masaomi Nangaku, Kazuhiko Ohe, Satoko Yamaguchi, Takashi Kadowaki International Journal of Clinical Oncology.2025; 30(11): 2178. CrossRef
Machine Learning‐Based Model for Predicting Recurrence‐Free Survival After Interventional Therapy in Malnourished Hepatocellular Carcinoma Patients Ningning Lu, Chunwang Yuan, Bin Sun, Xiongwei Cui, Wenfeng Gao, Yonghong Zhang Cancer Medicine.2025;[Epub] CrossRef
Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization and hepatic artery infusion chemotherapy in patients with BCLC stage 0-B hepatocellular carcinoma at high risk of recurrence following radical resection Xu Feng, Yupei Ao, Jiarui Liu, Jue Yuan, Zhengrong Shi, Chengjia Tang Frontiers in Pharmacology.2025;[Epub] CrossRef
Efficacy of postoperative adjuvant hepatic artery infusion chemotherapy for hepatocellular carcinoma in microvascular invasion: a propensity-matched score Xu Feng, Xinhua Wu, Kai Chen, Yupei Ao, Zhengrong Shi, Yixuan Gong Frontiers in Surgery.2025;[Epub] CrossRef
Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography Dong Wook Kim, Won Chang, So Yeon Kim, Young-Suk Lim, Jonggi Choi, Jungheum Cho, Jin-Wook Kim, Jai Young Cho, Sun Kyung Jeon, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Kyung-Suk Suh, Kwang-Woong Lee, Dong Ho Lee Clinical and Molecular Hepatology.2025; 31(4): 1285. CrossRef
Microvascular Invasion in Hepatocellular Carcinoma (Hcc): Implications and Strategy Andrea Celotti, M. Bonafede, G. Baiocchi, M. Tomasoni, F. Petrelli, M. Bonomi, G. Grizzi Current Surgery Reports.2025;[Epub] CrossRef
Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma Audrey Kapelanski-Lamoureux, Anthoula Lazaris, Nicholas Meti, Peter Metrakos Cancers.2025; 17(23): 3870. CrossRef
The therapeutic efficacy of radical resection for hepatocellular carcinoma varies markedly by tumor location: a retrospective real-world study Xu Feng, Yi-Qiu Wei, Jia-Rui Liu, Zheng-Rong Shi, Kai Chen, Yong-Shuang Lv Frontiers in Pharmacology.2025;[Epub] CrossRef
Serum Tumor Necrosis Factor-alpha Concentration and its Prognostic Implication in Hepatocellular Carcinoma Vembi Rizky Fatmawati, Ulfa Kholili, Husin Thamrin, Ricky Indra Alfaray Biomolecular and Health Science Journal.2025; 8(2): 105. CrossRef
Comparative effectiveness of several adjuvant therapies for patients with hepatocellular carcinoma with high-risk factors for recurrence after hepatectomy: a systematic review and meta-analysis Zejin Zhao, Haizhao Yi, Yue Xiao, Zhiyan Li, Jinlong Liu Frontiers in Medicine.2025;[Epub] CrossRef
Mechanism study of oleanolic acid derivative, K73-03, inducing cell apoptosis in hepatocellular carcinoma Jiaqi Wang, Chuchu Ma, Zhongyuan Tang, Zhengwu Sun, Eskandar Qaed, Xinming Chi, Jun Wang, Yazeed Jamalat, Zhaohong Geng, Zeyao Tang, Qiying Yao Cancer Cell International.2024;[Epub] CrossRef
Machine learning-based model for predicting tumor recurrence after interventional therapy in HBV-related hepatocellular carcinoma patients with low preoperative platelet-albumin-bilirubin score Qi Wang, Shugui Sheng, Yiqi Xiong, Ming Han, Ronghua Jin, Caixia Hu Frontiers in Immunology.2024;[Epub] CrossRef
Smoking as a Risk Factor for Very Late Recurrence in Surgically Resected Early-Stage Primary Hepatocellular Carcinoma Wei-Ru Cho, Chih-Chi Wang, Mu-Jung Tsai, Chih-Che Lin, Yi-Hao Yen, Chien Hung Chen, Yuan-Hung Kuo, Chih-Chien Yao, Chao-Hung Hung, Pao-Yuan Huang, An-Che Liu, Ming-Chao Tsai Clinical Medicine Insights: Oncology.2024;[Epub] CrossRef
Tubuloside B, a major constituent of Cistanche deserticola, inhibits migration of hepatocellular carcinoma by inhibiting Hippo-YAP pathway Jie Yao, Haoqiang Wan, Jingmei Zhang, Wanying Shen, Xiaofang Wei, Chenyan Shi, Baoru Ou, Dongyu Liu, Lanlan Ge, Jia Fei, Xiaobin Zeng Phytomedicine.2024; 129: 155552. CrossRef
Magnetic resonance elastography as a preoperative assessment for predicting intrahepatic recurrence in patients with hepatocellular carcinoma Jeong Hyun Lee, Jeong Ah Hwang, Kyowon Gu, Jaeseung Shin, Seungchul Han, Young Kon Kim Magnetic Resonance Imaging.2024; 109: 127. CrossRef
Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis Yuhua Wen, Lianghe Lu, Jie Mei, Yihong Ling, Renguo Guan, Wenping Lin, Wei Wei, Rongping Guo Journal of Hepatocellular Carcinoma.2024; Volume 11: 665. CrossRef
Bioengineered Organoids Offer New Possibilities for Liver Cancer Studies: A Review of Key Milestones and Challenges Abdullah Jabri, Jibran Khan, Bader Taftafa, Mohamed Alsharif, Abdulaziz Mhannayeh, Raja Chinnappan, Alaa Alzhrani, Shadab Kazmi, Mohammad Shabab Mir, Aljohara Waleed Alsaud, Ahmed Yaqinuddin, Abdullah M. Assiri, Khaled AlKattan, Yogesh K. Vashist, Dieter Bioengineering.2024; 11(4): 346. CrossRef
Glycemic Burden and Clinical Outcomes of Early Stage Hepatocellular Carcinoma after Curative Treatment Hyun Joo Lee, Moon Seok Choi, Byeong Geun Song, Won Seok Kang, Geum Youn Gwak, Myung Ji Goh, Yong Han Paik, Joon Hyeok Lee, Dong Hyun Sinn Cancers.2024; 16(15): 2652. CrossRef
TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma Dongbo Qiu, Tiantian Wang, Yi Xiong, Kun Li, Xiusheng Qiu, Yuan Feng, Qinghai Lian, Yunfei Qin, Kunpeng Liu, Qi Zhang, Changchang Jia Oncogenesis.2024;[Epub] CrossRef
Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues Hee Eun Jo, Sophallika Khom, Sumi Lee, Su Hyeon Cho, Shin Young Park, Ga Ram You, Hyosin Kim, Nah Ihm Kim, Jae-Ho Jeong, Jae Hyun Yoon, Misun Yun Scientific Reports.2024;[Epub] CrossRef
Combining transarterial chemoembolization, radiofrequency ablation, and iodine-125 seed implantation for recurrent hepatocellular carcinoma post-hepatectomy Yong Zhong, Li Wang, Weibin Dan, Dan Liang Diagnostic and Interventional Radiology.2024;[Epub] CrossRef
Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim European Journal of Internal Medicine.2023; 107: 66. CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim European Journal of Clinical Investigation.2023;[Epub] CrossRef
Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma Jing Liang, Yi Bai, Fu-Shuang Ha, Ying Luo, Hui-Ting Deng, Ying-Tang Gao World Journal of Gastrointestinal Oncology.2023; 15(1): 1. CrossRef
Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis” Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim Clinical and Molecular Hepatology.2023; 29(1): 173. CrossRef
Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment Sun Kyung Jeon, Dong Ho Lee, Bo‐Yun Hur, Sae‐Jin Park, Se Woo Kim, Junghoan Park, Kyung‐Suk Suh, Kwang‐Woong Lee, Nam‐Joon Yi, Joon Koo Han Journal of Magnetic Resonance Imaging.2023; 58(5): 1375. CrossRef
The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes Asanda Koza, Ricky H. Bhogal, Nicos Fotiadis, Vasileios K. Mavroeidis Biomedicines.2023; 11(4): 1062. CrossRef
Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma Xu Feng, Guo-Ying Feng, Jie Tao, Yu-Pei Ao, Xin-Hua Wu, Shi-Guai Qi, Zheng-Rong Shi Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10505. CrossRef
Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, Bo Yun Hur, Dong Ho Lee, Haeryoung Kim Clinical and Molecular Hepatology.2023; 29(3): 733. CrossRef
Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA Shushan Zhang, Yongquan Huang, Songying Pi, Hui Chen, Feile Ye, Chaoqun Wu, Liujun Li, Qing Ye, Yuhong Lin, Zhongzhen Su Journal of Nanobiotechnology.2023;[Epub] CrossRef
Inflammation-related prognostic markers in resected hepatocellular carcinoma Fabio Giannone, Nevena Slovic, Patrick Pessaux, Catherine Schuster, Thomas F. Baumert, Joachim Lupberger Frontiers in Oncology.2023;[Epub] CrossRef
A Real-World Comparative Study of Microwave and Radiofrequency Ablation in Treatment-Naïve and Recurrent Hepatocellular Carcinoma Soon Kyu Lee, Dong Jin Chung, Se Hyun Cho Journal of Clinical Medicine.2022; 11(2): 302. CrossRef
External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2022; 14(3): 711. CrossRef
Liver-specific LINC01146, a promising prognostic indicator, inhibits the malignant phenotype of hepatocellular carcinoma cells both in vitro and in vivo Xiaoyun Ma, Meile Mo, Chao Tan, Jennifer Hui Juan Tan, Huishen Huang, Bihu Liu, Dongping Huang, Shun Liu, Xiaoyun Zeng, Xiaoqiang Qiu Journal of Translational Medicine.2022;[Epub] CrossRef
MicroRNA miR-124-3p suppresses proliferation and epithelial–mesenchymal transition of hepatocellular carcinoma via ARRDC1 (arrestin domain containing 1) Qiannan Zhao, Fen Jiang, Hui Zhuang, Yanfeng Chu, Fang Zhang, Chenghong Wang Bioengineered.2022; 13(4): 8255. CrossRef
Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL Hankil Lee, Sungin Jang, Sang Hoon Ahn, Beom Kyung Kim Hepatology International.2022; 16(2): 294. CrossRef
Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, Young-Joo Won, Hyunsoon Cho Clinical and Molecular Hepatology.2022; 28(2): 242. CrossRef
A Radiomics Model Based on Gd-EOB-DTPA-Enhanced MRI for the Prediction of Microvascular Invasion in Solitary Hepatocellular Carcinoma ≤ 5 cm Chengming Qu, Qiang Wang, Changfeng Li, Qiao Xie, Ping Cai, Xiaochu Yan, Ernesto Sparrelid, Leida Zhang, Kuansheng Ma, Torkel B. Brismar Frontiers in Oncology.2022;[Epub] CrossRef
A Systematic Pan-Cancer Analysis of YY1 Aberrations and their Relationship with Clinical Outcome, Tumor Microenvironment, and Therapeutic Targets Xinghao Fu, Feihong Ji, Qi He, Xinguang Qiu, Fu Wang Journal of Immunology Research.2022; 2022: 1. CrossRef
Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study Jae Hyun Yoon, Sung Kyu Choi, Sung Bum Cho, Hee Joon Kim, Yang Seok Ko, Chung Hwan Jun World Journal of Gastroenterology.2022; 28(36): 5351. CrossRef
Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun Clinical and Molecular Hepatology.2022; 28(4): 876. CrossRef
Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim Cancers.2022; 14(20): 5002. CrossRef
New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim Clinical and Translational Gastroenterology.2022; 13(12): e00542. CrossRef
External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Viral Hepatitis.2021; 28(6): 951. CrossRef
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123. CrossRef
The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Journal of Hepatocellular Carcinoma.2021; Volume 8: 467. CrossRef
Does Neutrophil to Lymphocyte Ratio Have a Role in Identifying Cytokeratin 19-Expressing Hepatocellular Carcinoma? Chao-Wei Lee, Sey-En Lin, Ming-Chin Yu, Hao-Wei Kou, Cheng-Han Lee, Tony Kuo, Kuan-Chieh Lee, Hsin-I Tsai Journal of Personalized Medicine.2021; 11(11): 1078. CrossRef
Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1 Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho International Journal of Molecular Sciences.2021; 22(18): 10027. CrossRef
Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon International Journal of Molecular Sciences.2021; 22(19): 10271. CrossRef
Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro Translational Oncology.2021; 14(9): 101158. CrossRef
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park Journal of Viral Hepatitis.2021; 28(11): 1570. CrossRef
Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2021; 13(23): 5892. CrossRef
New next-generation microwave thermosphere ablation for small hepatocellular carcinoma Hideyuki Tamai, Jumpei Okamura Clinical and Molecular Hepatology.2021; 27(4): 564. CrossRef
Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis Ying Liu, Yuzhu Wang, Xinkun Guo, Yifeng He, Jian Zhou, Qianzhou Lv, Xiaowu Huang, Xiaoyu Li Frontiers in Oncology.2021;[Epub] CrossRef
Kwan Sik Lee, Young-Oh Kweon, Soon-Ho Um, Byung-Ho Kim, Young Suk Lim, Seung Woon Paik, Jeong Heo, Heon-Ju Lee, Dong Joon Kim, Tae Hun Kim, Young-Sok Lee, Kwan Soo Byun, Daeghon Kim, Myung Seok Lee, Kyungha Yu, Dong Jin Suh
Clin Mol Hepatol 2017;23(4):331-339. Published online September 26, 2017
Background/Aims Long-term data on antiviral therapy in Korean patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) are limited. This study evaluated the efficacy and safety of entecavir (ETV) and lamivudine (LAM) over 240 weeks.
Methods Treatment-naive patients with HBeAg-negative CHB were randomized to receive ETV 0.5 mg/day or LAM 100 mg/day during the 96 week double-blind phase, followed by open-label treatment through week 240. The primary endpoint was the proportion of patients with virologic response (VR; hepatitis B virus [HBV] DNA<300 copies/mL) at week 24. Secondary objectives included alanine aminotransferase (ALT) normalization and emergence of ETV resistance (week 96), VR and log reduction in HBV DNA levels (week 240), and safety evaluation.
Result s: In total, 120 patients (>16 years old) were included (ETV, n=56; LAM, n=64). Baseline characteristics were comparable between the two groups. A significantly higher proportion of ETV-treated patients achieved VR compared to LAM at week 24 (92.9% vs. 67.2%, P=0.0006), week 96 (94.6% vs. 48.4%, P<0.0001), and week 240 (95.0% vs. 47.6%, P<0.0001). At week 96, ALT normalization was observed in 87.5% and 51.6% of ETV and LAM patients, respectively (P<0.0001). Virologic breakthrough occurred in one patient (1.8%) receiving ETV and 26 patients (42.6%) receiving LAM (P<0.0001) up to week 96. Emergence of resistance to ETV was not detected. The incidence of serious adverse events was low and unrelated to the study medications.
Conclusions Long-term ETV treatment was superior to LAM, with a significantly higher proportion of patients achieving VR. Both treatments were well tolerated.
Citations
Citations to this article as recorded by
Viral oncogenesis in cancer: from mechanisms to therapeutics Qing Xiao, Yi Liu, Tingting Li, Chaoyu Wang, Sanxiu He, Liuyue Zhai, Zailin Yang, Xiaomei Zhang, Yongzhong Wu, Yao Liu Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
Cost–effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece Emmanouil Sinakos, Nandita Kachru, Christos Tsoulas, Sushanth Jeyakumar, Nathaniel J Smith, Alon Yehoshua, Evangelos Cholongitas Journal of Comparative Effectiveness Research.2024;[Epub] CrossRef
Entecavir: A Review and Considerations for Its Application in Oncology Tânia Lourenço, Nuno Vale Pharmaceuticals.2023; 16(11): 1603. CrossRef
No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir Hyunwoo Oh, Eileen L. Yoon, Dae Won Jun, Sang Bong Ahn, Hyo-Young Lee, Jae Yoon Jeong, Hyoung Su Kim, Soung Won Jeong, Sung Eun Kim, Jae-Jun Shim, Joo Hyun Sohn, Yong Kyun Cho Clinical Gastroenterology and Hepatology.2020; 18(12): 2793. CrossRef
Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review Raquel Scherer de Fraga, Victor Van Vaisberg, Luiz Cláudio Alfaia Mendes, Flair José Carrilho, Suzane Kioko Ono Journal of Gastroenterology.2020; 55(5): 496. CrossRef
Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma Mi Young Jeon, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang‐Hyub Han, Sang Hoon Ahn, Seung Up Kim Journal of Viral Hepatitis.2020; 27(9): 932. CrossRef
Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir Seung Bum Lee, Joonho Jeong, Jae Ho Park, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin, Bo Ryung Park, Eun Ji Park, Neung Hwa Park Clinical and Molecular Hepatology.2020; 26(3): 364. CrossRef
A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients Urbano Sbarigia, Talitha Vincken, Peter Wigfield, Mahmoud Hashim, Bart Heeg, Maarten Postma Journal of Comparative Effectiveness Research.2020; 9(15): 1051. CrossRef
Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults Roger Chou, Ian Blazina, Christina Bougatsos, Rebecca Holmes, Shelley Selph, Sara Grusing, Janice Jou JAMA.2020; 324(23): 2423. CrossRef
External validation of the modified PAGE‐B score in Asian chronic hepatitis B patients receiving antiviral therapy Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Beom Kyung Kim Liver International.2019; 39(9): 1624. CrossRef
Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials William W. L. Wong, Petros Pechivanoglou, Josephine Wong, Joanna M. Bielecki, Alex Haines, Aysegul Erman, Yasmin Saeed, Arcturus Phoon, Mina Tadrous, Mona Younis, Noha Z. Rayad, Valeria Rac, Harry L. A. Janssen, Murray D. Krahn Systematic Reviews.2019;[Epub] CrossRef
First
Prev
